Foghorn Therapeutics Inc.’s development program for FHD-286 has run into trouble as the US Food and Drug Administration has placed a partial clinical hold in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following a patient death. But the drug may still be able to move forward as the death was due to a problem that has occurred with some approved AML drugs.
Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.
